Industry

Recognition highlights Anumana’s leadership in AI-driven cardiovascular detection and clinical decision support CAMBRIDGE, Mass.–(BUSINESS WIRE)–Anumana, a leader in AI-powered cardiovascular detection algorithms, today announced it has been named to Fast Company’s prestigious 2026 Most Innovative Companies list in the Medical Devices category. The annual award recognizes hardware and technologies changing how healthcare is delivered and … [Read more…]

− Efforts Aimed at Facilitating Earlier Diagnosis, Coordinated Care, and Long-Term Patient Impact in ATTR-CM – − Alnylam to Host TTR Investor Webinar Today at 9:30 am ET – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced a set of strategic efforts designed to accelerate earlier recognition and improve … [Read more…]

First preclinical data on the Company’s lead program MOS101: a combination of ASTX295, a next-generation, clinical-stage MDM2 antagonist, and olaparib, an FDA-approved PARP inhibitor, in biomarker-selected solid tumors Additional data showcasing Mosaic’s Discovery Platform, PRIME, will be presented CAMBRIDGE, England–(BUSINESS WIRE)–Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) a clinical-stage oncology therapeutics company building the category … [Read more…]

— Acquisition Adds Clinical Stage Bispecific BCMAxCD3 T Cell Engager with Potential for Durable Immune Reset to Gilead’s Inflammation Portfolio — — Gilead Intends to Enter into a Strategic Collaboration with Galapagos on the Ouro Portfolio of Medicines — FOSTER CITY, Calif.–(BUSINESS WIRE)–#GILD–Gilead Sciences, Inc. (Nasdaq: GILD) announced today it has entered into a definitive … [Read more…]

Webcast to be held Monday, March 30th, 4:30 p.m. ET, register for the webcast here, or at the link provided below.  DALLAS–(BUSINESS WIRE)–Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning (“ML”) platform with multiple clinical stage drug programs, today … [Read more…]

LYON, France–(BUSINESS WIRE)–$MAAT #ASH–Regulatory News: MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer, today announced that Florent Malard, MD, PhD, hematology professor at Saint‑Antoine Hospital and Sorbonne University, presented the final results from … [Read more…]

GRAND RAPIDS, Mich.–(BUSINESS WIRE)–After a nationwide search, Priority Health, a Michigan-based, nationally recognized nonprofit health plan serving 1.4 million members, has named Brian Steele, D.O., as senior vice president and chief medical officer. He will join Priority Health on April 6, 2026. Dr. Steele will lead Priority Health’s clinical and pharmacy programs, the development and … [Read more…]

Milestone marks first of multiple planned diagnostic product launches on NGS roadmap Powered by the Archer platform technology, IDT empowers molecular pathology laboratories with first in vitro diagnostic BOULDER, Colo.–(BUSINESS WIRE)–#IVD–Global genomics leader Integrated DNA Technologies (IDT) today announced the launch of Archer FUSIONPlex™-HT Dx and VARIANTPlex™-HT Dx in vitro diagnostic (IVD) offerings. This milestone … [Read more…]

Scalable, parallel drug design: one researcher can run multiple campaigns simultaneously across targets and modalities From research goal to lab-ready sequences in hours: Latent-Y compresses weeks of expert work into autonomous design campaigns Lab-validated results across three antibody design campaigns: achieving a 67% target-level success rate with single-digit nanomolar affinities—without human filtering or intervention Powered … [Read more…]

-Accelerating commercialization of wireless power supplies for EVs and active pharmaceutical ingredients with an eye on the Indian and African markets- TOKYO–(BUSINESS WIRE)–#IITH–Dai Nippon Printing Co., Ltd. (DNP, TOKYO:7912) will establish a new research and development base in Telangana, India, in April 2026, to advance and reinforce its global R&D strategy. The base will be … [Read more…]